Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
One purpose of this trial is to extend the evidence basis for Mydayis in adult ADHD to include efficacy with a clinical ADHD symptom measure validated for DSM-5 adult ADHD. Another purpose of this trial is to re-examine the clinical efficacy of Mydayis later in the day on ADHD symptoms; the data on ADHD symptoms via the TASS 1 (Spencer et al. 2008) is a decade old and has not been examined in subsequent trials.
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female between the ages of 18-60 of all races and ethnicity.
Meets DSM V-TR criteria for a primary diagnosis of ADHD (including predominantly inattentive presentation, or combined presentation) as diagnosed via the Adult ADHD Clinician Diagnostic Scale version 1.2 (ACDS v1.2)
You may not be if
Meets DSM V-TR criteria for a primary diagnosis of hyperactive-impulsive type ADHD as diagnosed via the ACDS v1.2.
Any other current psychiatric disorder, determined via the M.I.N.I, which requires pharmacotherapy treatment.
Current suicidal ideation or history of suicide attempts, based on the Columbia- Suicide Severity Rating Scale(C-SSRS)
Lifetime history of bipolar disorder or any psychotic disorder as per the M.I.N.I
Pregnant, breastfeeding or women planning to become pregnant.
Positive urine drug toxicology are excluded.
Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.
Clareo Health | Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
